Log In
Print
BCIQ
Print
Print this Print this
 

morphine/oxycodone (MoxDuo IR) (Q8003 IR)

  Manage Alerts
Collapse Summary General Information
Company QRxPharma Ltd.
DescriptionImmediate-release combination of oxycodone and morphine
Molecular Target Mu opioid receptor (MOR) (OPRM1)
Mechanism of ActionMu opioid receptor agonist
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentRegistration
Standard IndicationPain
Indication DetailsTreat moderate to severe acute pain; Treat moderate to severe pain following bunionectomy; Treat moderate to severe post-operative pain following total knee replacement surgery
Regulatory Designation U.S. - Undisclosed Review (Treat moderate to severe acute pain)
Partner Allergan plc; Aspen Pharmacare Holdings Ltd.; Endo International plc; Teva Pharmaceutical Industries Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

5

$26.6M

$0.5M

$26.1M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today